Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations

Table 4 Main clinical characteristics of patients with atypical hemolytic uremic syndrome according complement abnormality

Gene	Atypical HUS incidence	Risk of death or renal failure within 1 yr	Risk of relapse	Relapse after transplantation	Plasma-therapy indication
CFH	20%-30%	50%-70%	50%	75%-90%	Yes
CFI	4%-10%	50%	10%-30%	45%-80%	Yes
MCP	5%-15%	0%-6%	70%-90%	< 20%	???
C3	2%-10%	60%	50%	40%-70%	Yes
CFB	1%-4%	50%	100%	100%	Yes
THBD	3%-5%	50%	30%	1%	Yes
Anti-CFH Ab	6%	30%-40%	40%-60%	Yes	Yes

HUS: Hemolytic uremic syndrome